Single-Center Experience with Axicabtagene-Ciloleucel (Axi-cel) and Tisagenlecleucel (Tisa-cel) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Comparable Response Rates and Manageable Toxicity

被引：5
|
作者：
Buecklein, Veit
Blumenberg, Viktoria
Ackermann, Josephine
Schmidt, Christian
Rejeski, Kai
Mueller, Niklas
Reischer, Anna
von Baumgarten, Louisa
Schoeberl, Florian
Humpe, Andreas
von Bergwelt, Michael
Subklewe, Marion
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-142932
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes
    Khurana, Arushi
    Bailey, Megumi
    Iqbal, Madiha
    Bansal, Radhika
    Lee, Catherine J.
    Hunter, Bradley
    Lunning, Matthew A.
    Jaglowski, Samantha
    Jain, Michael D.
    Dahiya, Saurabh
    Bachanova, Veronika
    Farooq, Umar
    Ahmed, Sairah
    Hill, Brian T.
    Munoz, Javier L.
    Patel, Krish
    Oluwole, Olalekan O.
    Lin, Yi
    BLOOD, 2022, 140 : 4657 - 4660
  • [42] Axicabtagene Ciloleucel (Axi-Cel) versus standard-of-care therapy in patients with relapsed/refractory diffuse large B cell lymphoma: The phase 3, randomized study, ZUMA-7
    Schmitz, N.
    Oluwole, O. O.
    Bishop, M. R.
    Gisselbrecht, C.
    Gordon, L. I.
    Kersten, M. J.
    Maloney, D. G.
    Caballero, M. D.
    Kuruvilla, J.
    Song, K. W.
    Jacobson, C. A.
    Nastoupil, L. J.
    Riedell, P.
    Jiang, Y.
    Rossi, J. M.
    Lee, L.
    Cheng, P.
    Locke, F. L.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 47 - 47
  • [43] Axicabtagene Ciloleucel (Axi-Cel) versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma: ZUMA-7, A Phase 3, Randomized Study
    Oluwole, Olalekan O.
    Bishop, Michael R.
    Gisselbrecht, Christian
    Gordon, Leo I.
    Kersten, Marie Jose
    Maloney, David G.
    Schmitz, Norbert
    Dolores Caballero, Maria
    Kuruvilla, John
    Song, Kevin W.
    Jacobson, Caron A.
    Nastoupil, Loretta J.
    Riedell, Peter
    Jiang, Yizhou
    Rossi, John M.
    Lee, Lillian
    Cheng, Paul
    Locke, Frederick L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S293 - S294
  • [44] Circulating tumor DNA (ctDNA) by clonoSEQ to monitor residual disease after axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL)
    Miles, Brodie
    Mao, Daqin
    Vardhanabhuti, Saran
    To, Christina Ann
    Schupp, Marco Andreas
    Shahani, Shilpa
    Xu, Hairong
    Munoz, Javier
    Westin, Jason
    Shen, Rhine
    Filosto, Simone
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] Health Utilities for Patients with Relapsed or Refractory Large B-Cell Lymphoma (R/R-LBCL): Ad Hoc Analysis From an Axicabtagene Ciloleucel (Axi-cel) Safety Management Study
    Lin, Vincent W.
    Jiang, Yizhou
    Chuang, Ling Hsiang
    Navale, Lynn
    Cheng, Paul
    Purdum, Anna
    BONE MARROW TRANSPLANTATION, 2018, 53 : 879 - 879
  • [46] Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    Lee, Dasom
    Kambhampati, Swetha
    Bobillo, Maria Silvina Odstrcil
    Adedokun, Babatunde
    Shadman, Mazyar
    Olson, Amanda L.
    Herrera, Alex F.
    Lee, Catherine J.
    Jacobson, Caron A.
    Bye, Matthew
    Hamadani, Mehdi
    Kim, Soyoung
    Dahiya, Saurabh
    Hu, Zhen-Huan
    Speth, Kelly
    To, Christina
    Mirjah, Debbie L.
    Best, Timothy
    Locke, Frederick L.
    Ahmed, Nausheen
    Tees, Michael T.
    Pasquini, Marcelo C.
    Ahmed, Sairah
    BLOOD, 2024, 144 : 527 - 528
  • [47] End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma
    Jacobson, Caron A.
    Locke, Frederick L.
    Miklos, David B.
    Herrera, Alex F.
    Westin, Jason R.
    Lee, Jennifer
    Rossi, John M.
    Sun, Jennifer
    Zheng, Lianqing
    Avanzi, Mauro P.
    Roberts, Zachary J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [48] End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma
    Jacobson, Caron A.
    Locke, Frederick L.
    Miklos, David B.
    Herrera, Alex F.
    Westin, Jason R.
    Lee, Jennifer
    Rossi, John M.
    Zheng, Lianqing
    Avanzi, Mauro P.
    Roberts, Zachary J.
    Sun, Jennifer
    BLOOD, 2018, 132
  • [49] Outcomes in large B-cell lymphoma progressing after axicabtagene ciloleucel (Axi-cel): Results from the US Lymphoma CAR-T Consortium.
    Spiegel, Jay Y.
    Dahiya, Saurabh
    Jain, Michael D.
    Nastoupil, Loretta J.
    Ghobadi, Armin
    Lin, Yi
    Lunning, Matthew Alexander
    Reagan, Patrick Michael
    McGuirk, Joseph
    Deol, Abhinav
    Munoz, Javier
    Locke, Frederick Lundry
    Neelapu, Sattva Swarup
    Tamaresis, John S.
    Rapoport, Aaron
    Miklos, David Bernard
    Hill, Brian Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [50] Prognostic impact of dose, duration, and timing of corticosteroid therapy in patients with large B-cell lymphoma treated with standard of care axicabtagene ciloleucel (Axi-cel).
    Strati, Paolo
    Furqan, Fateeha
    Westin, Jason
    Fayad, Luis
    Ahmed, Sairah
    Lee, Hun Ju
    Iyer, Swaminathan Padmanabhan
    Nair, Ranjit
    Nastoupil, Loretta J.
    Parmar, Simrit
    Rodriguez, Maria Alma
    Samaniego, Felipe
    Steiner, Raphael
    Wang, Michael
    Pinnix, Chelsea Camille
    Flowers, Christopher
    Horowitz, Sandra B.
    Classen, Catherine
    Mistry, Haleigh
    Neelapu, Sattva Swarup
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345